Feb 10 (Reuters) - AB Science SA :

* Announced on Monday the successful completion of afutility analysis related to the masitinib phase 3 trial for thetreatment of mild to moderate Alzheimer's disease

* Independent Data Safety Monitoring Committee (IDMC) hasrecommended the continuation of study

Source text for Eikon:

Further company coverage:

(Gdynia Newsroom)